Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges

Cancer immunotherapy has caused a paradigm shift from conventional therapies that directly target cancer cells to innovative therapies that utilize the host immune system. In particular, programmed cell death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) inhibitors have achieved an impressive breakthro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Kohei, Iwatsuki, Masaaki, Ajani, Jaffer A., Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382440/
https://www.ncbi.nlm.nih.gov/pubmed/32724880
http://dx.doi.org/10.1002/ags3.12348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382440/
https://www.ncbi.nlm.nih.gov/pubmed/32724880
http://dx.doi.org/10.1002/ags3.12348

Ejemplares similares